Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$4.8 million.

  • Keros Therapeutics' Change in Accured Expenses fell 15508.33% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.0 million, marking a year-over-year decrease of 16973.5%. This contributed to the annual value of $3.0 million for FY2024, which is 4384.63% down from last year.
  • Latest data reveals that Keros Therapeutics reported Change in Accured Expenses of -$4.8 million as of Q3 2025, which was down 15508.33% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Change in Accured Expenses peaked at $8.7 million during Q3 2024, and registered a low of -$5.4 million during Q1 2024.
  • Over the past 5 years, Keros Therapeutics' median Change in Accured Expenses value was $361000.0 (recorded in 2022), while the average stood at $551684.2.
  • As far as peak fluctuations go, Keros Therapeutics' Change in Accured Expenses surged by 449484.54% in 2022, and later tumbled by 64764.54% in 2023.
  • Quarter analysis of 5 years shows Keros Therapeutics' Change in Accured Expenses stood at -$97000.0 in 2021, then soared by 4494.85% to $4.3 million in 2022, then skyrocketed by 35.75% to $5.8 million in 2023, then plummeted by 122.45% to -$1.3 million in 2024, then crashed by 269.13% to -$4.8 million in 2025.
  • Its Change in Accured Expenses stands at -$4.8 million for Q3 2025, versus $2.7 million for Q2 2025 and -$3.6 million for Q1 2025.